The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.

The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.

Inclusion Criteria:

• Able to understand the study requirements and provide written informed consent before any study assessment is performed
• Male or female patients ≥ 18 to 45 years of age
• A diagnosis of type 1 diabetes

Exclusion Criteria:

• Women who are pregnant, lactating, or planning on pregnancy during the study
• History of cancer
• History of heart disease
• Recent infection